TRPV4 and neuropathy: Thalidomide- and paclitaxel-induced neuropathies activate TRPA1 and TRPV4 channels through the excessive production of oxidative stress by-products like H2O2 (Figure 2I), and the co-administration of TRPA1 (HC-030031) and TRPV4 (HC-067047) antagonists contributed to the complete ablation of allodynia and oxidative stress [79,113].